Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

Bernstein upgraded Novo Nordisk (NYSE:NVO) to “Market Perform” with a stock price of $84.86. The company’s stock shows slight ...

Kuykendall has been in his current role since July 2022. Interesting fact: He has worked with Novo Nordisk for more than 18 ...

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 725 from DKK 975 and keeps a Hold rating on the shares.Don't Miss Our ...

Weight-loss drugs have dominated the pharmaceutical market with their rapid success. Barclays head of European pharmaceuticals research, Emily Field, joins Seana Smith and Brad Smith on Morning Brief ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...